EPM
CBMG

Equitec Proprietary Markets’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Equitec Proprietary Markets’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$116K Buy
6,300
+100
+2% +$1.82K 0.03% 84
2020
Q3 		$114K Buy
+6,200
New +$104K 0.09% 62

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Equitec Proprietary Markets's CBMG Position: Q4 2020 in Review

Equitec Proprietary Markets increased its Cellular Biomedicine Group, Inc. (CBMG) stake by 1.6% in Q4 2020, buying an estimated $1.82K and bringing the position to 6,300 shares worth $116K. The position accounts for 0.03% of the portfolio, ranked #84.

Equitec Proprietary Markets first reported a position in CBMG in Q3 2020 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • Equitec Proprietary Markets held 6,300 shares of Cellular Biomedicine Group, Inc. worth $116K as of Q4 2020.
  • Equitec Proprietary Markets bought 100 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $1.82K.
  • Cellular Biomedicine Group, Inc. made up 0.03% of Equitec Proprietary Markets's portfolio in Q4 2020, its #84 holding.
  • Equitec Proprietary Markets first reported a position in Cellular Biomedicine Group, Inc. in Q3 2020 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Equitec Proprietary Markets's 13F filing for Q4 2020, filed 26 Jan 2021.